Digital Therapeutics Alliance (DTA) Releases Report to Provide Clarity on Industry Definitions and Market Landscape
Digital Therapeutics are not a thing of the future anymore but a growing market in the digital health landscape with products that increasingly influence the way healthcare is provided and consumed.
The Digital Therapeutics Alliance released a report defining the Digital Therapeutics (DTx) industry, definitions, market landscape and future trends.
Source – Digital Therapeutics Alliance
Digital therapeutics deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They incorporate advanced technology best practices and are validated by regulatory bodies as required to support product claims regarding risk, efficacy, and intended use.
The use of advanced technology empowers patients, healthcare providers and payers with intelligent tools to address a wide range of conditions and even provide novel therapy options for unmet medical needs. With the potential to be used in combination with existing therapies, digital therapeutics also offer the opportunity to enhance and support current medical treatments.
Delivering personalized treatment interventions to patients means all digital therapeutic products will need to adhere to industry-adopted core principles and best practices. The focus is on high quality, evidence-based therapies that make effective, patient-centered treatments accessible, that can scale across countries, and can integrate with different types of health care infrastructure.
Commenting on the release of the report and as an active alliance member, Jim O’Donoghue, President of S3 Connected Health highlighted that “Digital therapeutics offer huge potential to dramatically improve patient healthcare outcomes, and we must ensure that this opportunity is realized by engaging with industry stakeholders for effective adoption and integration of DTx in mainstream healthcare, clinical and reimbursement pathways.”
“This will enable DTx companies to provide solutions that are able to understand the patient context and provide the right treatment for them — in a way that can be personalized, relevant and context-aware.”
Over the coming months, S3 Connected Health are looking forward to actively working with the DTA to further develop best practices and frameworks that directly support the design, validation, utilization, and regulatory oversight of digital therapeutics across multiple cultures, languages, and national borders.
To access the full report visit: https://www.dtxalliance.org/wp-content/uploads/2018/09/DTA-Report_DTx-Industry-Foundations.pdf